Other ·Moderate evidence ·Reviewed May 2026
Natural sugar that prevents UTI-causing bacteria from adhering to urinary tract walls.
The bottom line
Evidence rating moderate. Most-documented uses: uti prevention, urinary tract health, bladder support. 16 sources indexed (2014–2026), with 4 interaction records on file.
Core mechanism
E. coli bacteria have FimH lectins that bind mannose residues. Oral D-mannose saturates these binding sites, preventing E. coli adhesion to uroepithelial cells and promoting bacterial flushing.13,14
Dissolve in water; take on empty stomach for quick urinary excretion
Dosing protocol
Most effective against E. coli UTI. Adjunct to acute care, not a substitute for antibiotics in pyelonephritis.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes D-Mannose Powder / Capsules.
Assumes 500-2,000 mg/day for prevention. Vendor basis: BulkSupplements powder, NOW/iHerb, Vitacost, and Amazon marketplace; acute multi-dose use costs more. Updated 2026-05-28.
How much you'd eat to match a supplemental dose.
Food sources are trace-level compared with urinary-health supplement dosing.
What to test, the optimal window inside the conventional range, and how long a response takes.
D-mannose (2 g per day) binds FimH adhesin on uropathogenic E. coli and reduces recurrent UTI rates in women; effect comparable to low-dose prophylactic antibiotics in RCT.13,14
Best for E. coli UTIs specifically. Track UTI frequency and dipstick (leukocyte esterase, nitrites).
Where this appears in the symptom-to-supplement map, ranked by relevance.
D-mannose binds FimH adhesin on uropathogenic E. coli, preventing adherence to bladder uroepithelium.4,7
RCT evidence compares favorably with low-dose prophylactic antibiotics in women.
D-mannose may reduce frequency driven by recurrent low-grade urinary infection by limiting E. coli adhesion to the bladder wall, but it does not address non-infectious overactivity.13,1
Useful only when frequency is tied to recurrent UTIs; see a clinician for a urine test if symptoms recur.
D-mannose may help when bladder discomfort is partly driven by recurrent E. coli infection rather than the interstitial cystitis process itself.13,1
Does not treat interstitial cystitis directly; useful only if recurrent UTIs are also present and confirmed by a clinician.
Evidence-based stacks that include it, with the exact dose and timing each one uses.
D-Mannose is biologically plausible for reducing bacterial adhesion, but evidence is mixed and a large recent randomized trial found no meaningful prevention benefit in primary care. Treat it as optional rather than foundational.13,14
D-mannose prevents E. coli adhesion to uroepithelium; probiotics support gut and urogenital flora that resists pathogen colonization.
Recommendation: Combine for recurrent UTI prevention: D-mannose 2 g/day plus L. rhamnosus or reuteri strains.
These act through complementary anti-uropathogen mechanisms, pairing bacterial anti-adhesion with competitive colonization to support urinary tract defense.
Recommendation: Reasonable to combine for recurrent UTI prophylaxis. No timing constraint required.
D-Mannose and the probiotic yeast Saccharomyces boulardii have been combined as a non-antibiotic UTI prophylaxis strategy. A randomized pilot study gave D-Mannose 500 mg plus S. boulardii 3 billion CFU after cystoscopy and reported lower post-procedure UTI incidence and less urinary discomfort versus no treatment. The pairing is mechanistically rational because the two ingredients target distinct steps (urinary bacterial anti-adhesion and flora restoration) and there is no absorption or pharmacological conflict between a poorly metabolized sugar and a transient gut-colonizing yeast.
Recommendation: Reasonable to combine for recurrent UTI prophylaxis. Typical regimens use D-Mannose 1.5 to 2 g once or twice daily with S. boulardii 250 to 500 mg (roughly 3 to 10 billion CFU) daily. No timing separation is required; both can be taken together. Maintain hydration to support urinary flushing. People who are critically ill, immunocompromised, or have a central venous catheter should avoid live S. boulardii because of a rare risk of fungemia.
D-Mannose and Vitamin C are frequently combined in UTI prevention products, often alongside cranberry. In trial arms that paired D-Mannose with vitamin C (and cranberry), investigators reported reductions in recurrent UTI episodes versus placebo, though the independent contribution of vitamin C is hard to isolate and its urine-acidifying effect is modest and inconsistent. There is no absorption competition or pharmacological conflict between the two: D-Mannose is a poorly metabolized sugar cleared by the kidneys and vitamin C is a water-soluble vitamin, and both reach the urine where their effects converge.
Recommendation: Acceptable to combine for urinary support. A common approach is D-Mannose 1.5 to 2 g once or twice daily with vitamin C 250 to 500 mg daily. No timing separation is needed. Keep vitamin C at moderate doses; very high doses (above roughly 2 g per day) can cause GI upset and, in predisposed people, raise oxalate stone risk. Do not rely on this combination to treat an established symptomatic infection, which warrants medical assessment.
Numbered references. Citations throughout the page link here.
Vargas CEF, Mutarelli A, Menegardo LG et al.. Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials. Jornal brasileiro de nefrologia. 2025
Network meta-analysis of 50 RCTs found D-mannose significantly reduced UTI incidence vs placebo (RR 0.34, 0.21-0.56).
Evidence is uncertain whether D-mannose prevents or treats UTIs; more well-designed RCTs with adequate power are needed.
Kyriakides R, Jones P, Somani BK. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. European urology focus. 2021
Pooled RR of UTI recurrence comparing D-mannose to placebo was 0.23 (95% CI 0.14-0.37), suggesting protective effect against UTI recurrence.
Singh RG, Nguyen E, Zhao Y et al.. A randomized, triple-blind, placebo-controlled, parallel study of the efficacy of D-mannose for urinary tract infection symptoms in women. Current urology. 2026
Riemma G, Vinci D, La Verde M et al.. Adding collagen, propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: a single-blind randomized controlled trial. Expert review of anti-infective therapy. 2025
Wang J, Mei L, Wen H et al.. D-mannose enhances immune function and modulates gut microbiota composition in adult cats: A randomized controlled trial. Research in veterinary science. 2025
Rau M, Santelli A, Martí S et al.. Randomized clinical trial of non-antibiotic prophylaxis with d-Mannose plus Proanthocyanidins vs. Proanthocyanidins alone for urinary tract infections and asymptomatic bacteriuria in de novo kidney transplant recipients: The Manotras study. Nefrologia. 2024
In 308 women, D-mannose (2g/day) reduced recurrent UTI rate to 14.6% vs 60.8% no prophylaxis; comparable to nitrofurantoin (20.4%) with fewer side effects.
Exogenous D-mannose saturates E. coli FimH adhesins, preventing adhesion to uroplakin receptors on bladder epithelium and facilitating bacterial clearance.
D-mannose at clinical dosages does not affect E. coli metabolism or induce stable FimH variants, supporting long-term safety.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack